Physician profile
John Keller
NPI 1316488463
$1,499.44
in general payments reported to CMS, 2019-2025
20 companies · $15.34 in 2025
The $15.34 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $577 · 2024: $907 · 2025: $15.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $264.46 | 2023-2024 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $207.11 | 2023-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $166.01 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $139.14 | 2023-2025 | |
| Novo Nordisk INC | $117.04 | 2023-2024 | Ozempic, Rybelsus |
| Indivior INC. | $90.44 | 2023-2024 | Sublocade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.17 | 2023-2024 | Jardiance |
| Pfizer INC. | $64.85 | 2023-2024 | |
| Astellas Pharma US INC | $57.53 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $46.68 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.92 | 2023-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $41.37 | 2023 | |
| Esperion Therapeutics, INC. | $35.61 | 2023 | Nexletol |
| Ironwood Pharmaceuticals, INC | $33.23 | 2023-2024 | Linzess |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.48 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $20.10 | 2023 | Quviviq |
| Corium, LLC | $18.40 | 2024 | Azstarys |
| Mylan Specialty L.P. | $17.15 | 2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $16.04 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $13.71 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.